LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc
Search

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

497.91 -0.22

Strong Buy

Price update 17 cze 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

492.76

Max

507.15

Key metrics

By Trading Economics

Income

-36M

-94M

Sales

-9.7M

311M

EPS

-1.38

Profit margin

-30.318

Employees

915

EBITDA

-36M

-86M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.46% upside

Dividends

By Acuity

Next Earnings

4 sie 2026

Market Stats

By TradingEconomics

Market Cap

-481M

11B

Previous open

498.13

Previous close

497.91

News Sentiment

By Acuity

50%

50%

155 / 342 Ranking in Healthcare

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat